RecruitingNot Applicable

Liposomal Bupivacaine and Bupivacaine for TTMPB in Median Sternotomy

China38 participantsStarted 2024-10-24

Plain-language summary

In light of the ongoing controversy surrounding the efficacy of bupivacaine liposomes, our study was designed to investigate, for the first time, the differential postoperative analgesic effects between bupivacaine liposomes combined with bupivacaine hydrochloride and bupivacaine hydrochloride alone in transverse thoracic muscle plane block treatment. The aim is to provide evidence-based medical guidance for drug selection in regional block local anesthesia.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18-90 years; * ASA Class I \~ III; * Patients undergoing elective median sternotomy. Exclusion Criteria: * Emergency surgery; * Re-operation; * Coagulation dysfunction; * Preoperative left ventricular function was poor (ejection fraction \<35%); * Systemic infection or injection site infection; * Neuromuscular diseases; * Mental illness; * Dependence on psychotropic drugs; * Allergic to bupivacaine liposomes and bupivacaine; * Patients have participated in previous trials or have been determined by a surgeon or anesthesiologist to be unsuitable for randomization; * Failure to obtain written informed consent from the patient or his/her representative

What they're measuring

Third-day opioid consumption

Timeframe: 48-72 hours after surgery

Trial details

NCT IDNCT06646172

SponsorTongji Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-24

Contact for this trial

Liu Tianzhu, M.D.

13098866448 liutzh@126.com

View on ClinicalTrials.gov More Median Sternotomy trials